Proton MRSI Of Human Breast Cancer At 3 And 7 Tesla
Peter B Barker, Professor
Radiology And Radiological Sciencesjohns Hopkins University
Grant 5R01CA125258-02 from National Cancer Institute, IRG: MEDI
Abstract: Breast cancer is the most common form of cancer in women. In the year 2004, it was estimated that approximately 217,000 new cases of breast cancer were diagnosed in the United States, and that 40,000 deaths were attributed to the disease. The key to successful treatment of breast cancer is early diagnosis, and the use of widespread mammography screening has resulted in significant improvements in breast cancer survival rates. However, a major problem with mammography is a lack of specificity; in some studies, as many of 70-80% of suspicious lesions on mammography referred for biopsy ultimately have a benign final diagnosis. These ´unnecessary" biopsies represent a significant economic burden on health care systems, and are also invasive and unpleasant for the patient. Therefore, there is a need for the development of new non-invasive, cost-effective, and safe diagnostic imaging procedures with enhanced specificity and sensitivity. Proton MR spectroscopic imaging (MRSI) is a non-invasive metabolic imaging technique that shows promise for the non-invasive diagnosis of human breast cancer. Preliminary data from our group and others suggests that an elevated choline signal (detected in the proton MR spectrum) is a marker of malignant breast disease. However, the low signal-to-noise ratio of proton MRSI currently limits this methodology to quite large lesions (e.g. 1 cm or greater), and makes detection of small Cho signals difficult. Also, few previous studies have investigated the spatial distribution of Cho in breast cancer lesions. In this proposal, we therefore propose to develop methods for MRSI on high field MR systems (3 and 7 Tesla) that are expected to exhibit higher sensitivity and resolution than lower field scanners. Methods will be developed for full breast coverage at high magnetic fields in short scan times, using phased-array receiver coils, and optimal water and lipid suppression. Methods will also be developed for the quantitative determination of lesion choline concentrations. These methods will be developed in years 1 and 2, and, in years 3 through 5, the clinical value of MRSI will be investigated. Specifically, choline levels will be compared between histologically defined tissue types (malignant and benign), in patients who are scheduled for breast biopsy. The sensitivity and specificity of proton MRSI in this patient group will be determined, and compared between field strengths. In addition, the diagnostic value of MRSI will be compared to that of conventional MRI in the same population
Project start date: 2007-08-08
Project end date: 2012-07-31
Sponsored Links Lab Supply Mall http://www.labsupplymall.com
Grants awarded to Peter B Barker
Proton MRSI Of Human Breast Cancer At 3 And 7 Tesla
Peter B Barker, Professor
Radiology And Radiological Sciencesjohns Hopkins University
Grant 5R01CA125258-02 from National Cancer Institute, IRG: MEDI
Abstract: Breast cancer is the most common form of cancer in women. In the year 2004, it was estimated that approximately 217,000 new cases of breast cancer were diagnosed in the United States, and that 40,000 deaths were attributed to the disease. The key to successful treatment of breast cancer is early diagnosis, and the use of widespread mammography screening has resulted in significant improvements in breast cancer survival rates. However, a major problem with mammography is a lack of specificity; in some studies, as many of 70-80% of suspicious lesions on mammography referred for biopsy ultimately have a benign final diagnosis. These ´unnecessary" biopsies represent a significant economic burden on health care systems, and are also invasive and unpleasant for the patient. Therefore, there is a need for the development of new non-invasive, cost-effective, and safe diagnostic imaging procedures with enhanced specificity and sensitivity. Proton MR spectroscopic imaging (MRSI) is a non-invasive metabolic imaging technique that shows promise for the non-invasive diagnosis of human breast cancer. Preliminary data from our group and others suggests that an elevated choline signal (detected in the proton MR spectrum) is a marker of malignant breast disease. However, the low signal-to-noise ratio of proton MRSI currently limits this methodology to quite large lesions (e.g. 1 cm or greater), and makes detection of small Cho signals difficult. Also, few previous studies have investigated the spatial distribution of Cho in breast cancer lesions. In this proposal, we therefore propose to develop methods for MRSI on high field MR systems (3 and 7 Tesla) that are expected to exhibit higher sensitivity and resolution than lower field scanners. Methods will be developed for full breast coverage at high magnetic fields in short scan times, using phased-array receiver coils, and optimal water and lipid suppression. Methods will also be developed for the quantitative determination of lesion choline concentrations. These methods will be developed in years 1 and 2, and, in years 3 through 5, the clinical value of MRSI will be investigated. Specifically, choline levels will be compared between histologically defined tissue types (malignant and benign), in patients who are scheduled for breast biopsy. The sensitivity and specificity of proton MRSI in this patient group will be determined, and compared between field strengths. In addition, the diagnostic value of MRSI will be compared to that of conventional MRI in the same population
Project start date: 2007-08-08
Project end date: 2012-07-31
1R01CA125258-01A1 (2007): $398775
Proton MR Spectroscopic Imaging In Human Breast Cancer
Peter B Barker, Associate Professor
Radiology And Radiological Sciencesjohns Hopkins University
w400 Wyman Park Building
baltimore, Md 212182680
Grant 1R21CA091798-01 from National Cancer Institute, IRG: ZCA1
Abstract: Breast cancer is the most common form of cancer in women. In the year 2000, it is predicted that approximately 180,000 new cases of breast cancer will be diagnosed in the United States, and 40,000 women will die from the disease. The key to successful treatment of breast cancer is early diagnosis, and the use of widespread mammography screening has resulted in significant improvements in breast cancer survival rates. However, a major problem with mammography is a lack of specificity; 70-80% of suspicious lesions on mammography referred for biopsy ultimately have a benign final diagnosis. These "unnecessary" biopsies represent a significant economic burden on health care systems, and are also invasive and unpleasant for the patient. Therefore, there is a need for the development of new non-invasive, cost-effective, and safe imaging procedures with enhanced specificity and sensitivity. Proton MR spectroscopic imaging (MRSI) is a non-invasive metabolic imaging technique, which has yet to be applied to human breast cancer. Preliminary data from our group and others, based on cell preparations, in vitro studies and single-voxel human spectroscopy, suggest that an elevated composite choline signal (detected in the proton MR spectrum) is a marker of malignant breast disease. Benign lesions and normal breast tissue have little or no detectable choline signal. However, technical developments are required before proton MRSI can become a clinical procedure for evaluating breast cancer. These include maximizing spatial resolution, optimizing water and lipid suppression techniques, development of quantitation methodology, and providing whole breast coverage within a clinically acceptable scan time. We will develop and test these techniques in years one and two of this proposal (phase I, R21), and in years 3 and 4 (phase II, R33) we will apply these techniques to a trial of proton MRSI in human breast cancer. Specifically, choline levels will be compared between histologically defined tissue types, in patients who are scheduled for breast biopsy. The sensitivity and specificity of proton MRSI in this patient group will be determined. The techniques developed in this proposal will also assist in the translation of proton MRSI to other organ systems and pathologies, and increase the acceptance of clinical proton MRSI as a diagnostic imaging modality
Keywords: breast neoplasm, diagnosis design /evaluation, mammography, nuclear magnetic resonance spectroscopy choline, method development clinical research, female, human subject, women`s health
Project start date: 2001-09-01
Project end date: 2003-08-31
1R21CA091798-01 (2001): $158978
5R33CA091798-04 (2005): $279381
4R33CA091798-03 (2004): $272973
BRAIN CHEMISTRY BY MR SPECTROSCOPIC IMAGING
Peter B Barker, Associate Professor
Hugo W. Moser Res Inst Kennedy Krieger Kennedy Krieger, Inc. Baltimore, Md 21205
Grant 5P41RR015241-040002 from National Center For Research Resources, IRG: ZRG1
Keywords: biomedical resource, brain imaging /visualization /scanning, chemistry, bioimaging /biomedical imaging, clinical research, nuclear magnetic resonance spectroscopy
Project start date: 2004-09-01
Project end date: 2005-08-31
Related Publications
Measurement of T1 and T2 in the cervical spinal cord at 3 tesla. Magn Reson Med. 2008 Jul; 60( 1): 213-9. PMID: 18581383 3T MR with diffusion tensor imaging and single-voxel spectroscopy in giant axonal neuropathy. J Magn Reson Imaging. 2008 Jul; 28( 1): 236-41. PMID: 18581347 Regional apparent metabolite concentrations in young adult brain measured by (1)H MR spectroscopy at 3 Tesla. J Magn Reson Imaging. 2008 Mar; 27( 3): 489-99. PMID: 18307197 A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med. 2008 Feb 13. [Epub ahead of print] PMID: 18280205 Molecular characterization of musculoskeletal tumors by proton MR spectroscopy. Semin Musculoskelet Radiol. 2007 Sep; 11( 3): 240-5. Review. PMID: 18260034 Spatial effects in the detection of gamma-aminobutyric acid: improved sensitivity at high fields using inner volume saturation. Magn Reson Med. 2007 Dec; 58( 6): 1276-82. PMID: 17969062 Proton magnetic resonance spectroscopy in obsessive-compulsive disorder: a pilot investigation comparing treatment responders and non-responders. Psychiatry Res. 2007 Nov 15; 156( 2): 175-9. Epub 2007 Sep 29. PMID: 17904826 Proton MR spectroscopic imaging of the medulla and cervical spinal cord. J Magn Reson Imaging. 2007 Oct; 26( 4): 1101-5. PMID: 17896355 Magnetic resonance perfusion imaging in acute middle cerebral artery stroke: Comparison of blood volume and bolus peak arrival time. J Stroke Cerebrovasc Dis. 1998 January - February; 7( 1): 17-23. PMID: 17895052 A neurologic presentation of familial hemophagocytic lymphohistiocytosis which mimicked septic emboli to the brain. J Child Neurol. 2007 Jul; 22( 7): 863-8. PMID: 17715280 In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla. Magn Reson Med. 2007 Jun; 57( 6): 977-82. PMID: 17534922 
Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy. AJR Am J Roentgenol. 2007 Jun; 188( 6): 1513-20. PMID: 17515370 Correction of symptomatic cerebral malperfusion due to acute type I aortic dissection by transcarotid stenting of the innominate and carotid arteries. J Vasc Surg. 2006 Nov; 44( 5): 1091-6. PMID: 17098547 
Diffusion tensor imaging in children and adolescents: reproducibility, hemispheric, and age-related differences. Neuroimage. 2007 Jan 15; 34( 2): 733-42. Epub 2006 Nov 7. PMID: 17092743 Neural correlates of modality-specific spatial extinction. J Cogn Neurosci. 2006 Nov; 18( 11): 1889-98. PMID: 17069479 Evidence for cortical dysfunction and widespread manganese accumulation in the nonhuman primate brain following chronic manganese exposure: a 1H-MRS and MRI study. Toxicol Sci. 2006 Dec; 94( 2): 351-8. Epub 2006 Sep 12. PMID: 16968886 Optimized detection of lactate at high fields using inner volume saturation. Magn Reson Med. 2006 Oct; 56( 4): 912-7. PMID: 16964614 Childhood obstructive sleep apnea associates with neuropsychological deficits and neuronal brain injury. PLoS Med. 2006 Aug; 3( 8): e301. PMID: 16933960 Restoring cerebral blood flow reveals neural regions critical for naming. J Neurosci. 2006 Aug 2; 26( 31): 8069-73. PMID: 16885220 Neuroimaging of phakomatoses. Semin Pediatr Neurol. 2006 Mar; 13( 1): 48-62. Review. PMID: 16818176